Jazz Pharmaceuticals PLC (JAZZ) Expected to Post Quarterly Sales of $474.70 Million

Analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to post sales of $474.70 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Jazz Pharmaceuticals’ earnings, with the highest sales estimate coming in at $496.78 million and the lowest estimate coming in at $449.47 million. Jazz Pharmaceuticals posted sales of $436.40 million during the same quarter last year, which suggests a positive year over year growth rate of 8.8%. The company is expected to announce its next earnings results on Tuesday, February 26th.

On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.89 billion for the current year, with estimates ranging from $1.86 billion to $1.92 billion. For the next fiscal year, analysts expect that the firm will post sales of $2.13 billion, with estimates ranging from $1.99 billion to $2.24 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a return on equity of 25.44% and a net margin of 28.09%. The business had revenue of $469.37 million for the quarter, compared to the consensus estimate of $482.64 million. During the same quarter in the prior year, the business earned $3.22 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 14.0% on a year-over-year basis.

JAZZ has been the topic of a number of analyst reports. Evercore ISI reissued a “buy” rating on shares of Jazz Pharmaceuticals in a report on Friday, July 13th. Seaport Global Securities reissued a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 9th. Wells Fargo & Co reissued a “buy” rating and set a $195.00 target price (up previously from $182.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, August 15th. Stifel Nicolaus boosted their target price on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $213.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, August 8th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $191.94.

Jazz Pharmaceuticals stock opened at $145.57 on Friday. Jazz Pharmaceuticals has a 12 month low of $130.15 and a 12 month high of $184.00. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $9.93 billion, a P/E ratio of 15.23, a PEG ratio of 0.89 and a beta of 1.06.

In other news, CEO Bruce C. Cozadd sold 1,300 shares of the company’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $159.45, for a total value of $207,285.00. Following the transaction, the chief executive officer now owns 278,615 shares of the company’s stock, valued at $44,425,161.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $175.70, for a total transaction of $35,140.00. Following the completion of the transaction, the executive vice president now directly owns 25,572 shares in the company, valued at approximately $4,493,000.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,730 shares of company stock worth $2,796,532. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Stratos Wealth Partners LTD. bought a new position in Jazz Pharmaceuticals in the third quarter valued at $106,000. Tiverton Asset Management LLC bought a new position in Jazz Pharmaceuticals in the second quarter valued at $198,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the second quarter valued at $204,000. FDx Advisors Inc. bought a new position in Jazz Pharmaceuticals in the second quarter valued at $244,000. Finally, Cadence Capital Management LLC bought a new position in Jazz Pharmaceuticals in the third quarter valued at $263,000. 92.95% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply